Pihlmann Kristensen, Maria; Korsgaard, Ulrik; Timm, Signe; Frøstrup Hansen, Torben; Zlobec, Inti; Kjær-Frifeldt, Sanne; Hager, Henrik (2024). Immunohistochemical analysis of tumor budding in stage II colon cancer: exploring zero budding as a prognostic marker. (In Press). Virchows Archiv Springer 10.1007/s00428-024-03860-2
|
Text
s00428-024-03860-2.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview |
Tumor budding, a biomarker traditionally evaluated using hematoxylin and eosin (H&E) staining, has gained recognition as a prognostic biomarker for stage II colon cancer. Nevertheless, while H&E staining offers valuable insights, its limitations prompt the utilization of pan-cytokeratin immunohistochemistry (IHC). Consequently, this study seeks to evaluate the prognostic significance of tumor budding using IHC in a contemporary cohort of stage II colon cancer patients, aiming to deepen our understanding of this critical facet in cancer prognosis. We conducted a retrospective, population-based cohort study including 493 patients with stage II colon cancer and evaluated tumor budding using IHC, following the H&E-based guidelines proposed by the International Tumor Budding Consensus Conference Group. Correlation between H&E-based and IHC-based tumor budding was assessed using a four-tiered scoring system that included a zero budding (Bd0) category. Survival analyses explored the prognostic significance of tumor budding assessed by IHC and H&E. As expected, IHC-based tumor budding evaluation yielded significantly higher bud counts compared to H&E (p < 0.01). Interestingly, 21 patients were identified with no tumor budding using IHC. This was associated with significantly improved recurrence-free survival (HR = 5.19, p = 0.02) and overall survival (HR = 4.47, p = 0.04) in a multivariate analysis when compared to tumors with budding. The Bd0 category demonstrated a 100% predictive value for the absence of recurrence. In conclusion, IHC-based tumor budding evaluation in stage II colon cancer provides additional prognostic information. The absence of tumor budding is associated with a favorable prognosis and may serve as a potential marker for identifying patients with no risk of recurrence.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Zlobec, Inti |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
0945-6317 |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
09 Jul 2024 09:42 |
Last Modified: |
10 Jul 2024 07:44 |
Publisher DOI: |
10.1007/s00428-024-03860-2 |
PubMed ID: |
38977466 |
Uncontrolled Keywords: |
Immunohistochemistry Scoring system Stage II colon cancer Survival Tumor budding |
BORIS DOI: |
10.48350/198715 |
URI: |
https://boris.unibe.ch/id/eprint/198715 |
Actions (login required)
 |
Edit item |